The performance of the cytotoxicity test serves the medical device manufacturer to prove the biocompatibility of its product, e.g. in the context of a CE marking, and to identify biological hazards and to assess the risk of the product already during product development.

On Sept. 26, 2023, Dr. Sabine Gorynia, EVP GBA Group Pharma & Medical Devices, Torben Giese, Chief Strategy Officer GBA Group, and Felix Bunde, Managing Director GBA MDS, visited the new colleagues at ICCR Roßdorf GmbH.

GBA Group is expanding its range of toxicology services for customers in the chemical, medical device and pharmaceutical industries with the acquisition of ICCR-Roßdorf GmbH (ICCR-Roßdorf). This acquisition underlines GBA Group's ambition to position itself broadly as an international life science service provider through targeted portfolio expansions and investment in leading CROs.

After two years it is finally time again: from 07. - 11.10.2023 the food and beverage exhibition Anuga, will take place in Cologne.

This time under the guiding theme "Sustainable Growth" to exchange ideas about meat substitutes, superfoods, sustainable production and many other trend topics. Anuga is considered the world's largest trade fair for the food and nutrition industry and combines a total of 10 trade fairs covering a wide range of topics in the food industry.

"Global efforts in the area of health care will continue to grow in the future. With this in mind, GBA Group has significantly expanded its Pharma & Medical Devices portfolio and will continue to invest in this growth market to position itself as a professionally comprehensive and internationally positioned laboratory and service provider for the benefit of our society." Steffen Walter, CEO.